ArticleJournal of orthopaedics2025
Clinical evaluation of therapeutic efficacy of Teriparatide in osteoporotic patients with vertebral degeneration.
Article in Journal of orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Three-Dimensionally Printed Scaffolds and Drug Delivery Systems in Treatment of Osteoporosis.Biomimetics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objective: Osteoporosis is a common age-associated bone disease characterized by the decreased bone density and compromised bone strength. Osteoporotic patients are always at a risk of severe fractures and they experience chronic lumbar pain, highlighting the need for an effective treatment while having lowest side effects. This clinical evaluation of three years from 2018 to 2021 at a single clinic in western Tehran, Iran was aimed to evaluate the therapeutic effects of a biosimilar recombinant teriparatide traded as 'Cinnopar®' to alleviate the back pain and manage thoracolumbar osteoporosis. Methods: In this study, a total of 180 osteoporotic patients diagnosed with lower back pain, were enrolled and later on 14 patients were excluded from the study due to lack of cooperation or follow-up. Patients were randomly assigned into two groups, one those who are willingly will be receiving CinnoPar® and second group who will be receiving bisphosphonates at an optimal monthly dose. Data was collected through reviews of medical records and comprehensive regular follow-up was performed via phone interviews to evaluate bone density and pain levels during specific intervals of time. Oswestry Disability Index (ODI) was developed and Short Form Health Survey (SF-36) was performed to analyses the results from two under treatment groups. Results and conclusion: Significant improvement in pain and functional ability was observed in the patients who received CinnoPar® after two years as compared to the bisphosphonate group (P < 0.05). It was also reported that patients who received CinnoPar® showed improvements in social functioning and pain reduction over the same period of time (P < 0.05). CinnoPar® showed promising results and fall under a minimally invasive treatment category for reducing the lower back pain and managing osteoporosis in lumbar and thoracic vertebrae while having few side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.